Venlafaxine’s therapeutic reference range in the treatment of depression revised: a systematic review and meta-analysis
2023 · Psychopharmacology · 23 citations
https://doi.org/10.1007/s00213-023-06484-7
M
Maike Scherf‐Clavel
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
73
Papers
516
Citations
14
h-index
21
i10-index
Maike Scherf‐Clavel is an academic researcher from Universitätsklinikum Würzburg. The author has contributed to research in topics: Treatment of Major Depression & Pharmacogenetics and Drug Metabolism & Bipolar Disorder and Treatment. The author has an h-index of 14, co-authored 63 publications.
ORCID: 0000-0002-4780-612XPapers by this author
worksEffect of CYP2D6 pharmacogenetic phenotype and phenoconversion on serum concentrations of antidepressants and antipsychotics: a retrospective cohort study
2023 · International Journal of Clinical Pharmacy · 18 citations
https://doi.org/10.1007/s11096-023-01588-8
<scp><i>ABCB1</i></scp> Gene Variants and Antidepressant Treatment Outcomes: A Systematic Review and Meta‐Analysis Including Results from the <scp>CAN‐BIND</scp>‐1 Study
2023 · Clinical Pharmacology & Therapeutics · 15 citations
https://doi.org/10.1002/cpt.2854
Higher venlafaxine serum concentrations necessary for clinical improvement? Time to re-evaluate the therapeutic reference range of venlafaxine
2020 · Journal of Psychopharmacology · 14 citations
https://doi.org/10.1177/0269881120936509
TDM von Antidepressiva verkürzt Klinikaufenthalt
2024 · Der Nervenarzt · 2 citations
https://doi.org/10.1007/s00115-024-01636-2
Risk Phenotypes, Comorbidities, Pharmacotherapy, and Electroconvulsive Therapy (ECT) in a Cohort with Difficult-to-Treat Depression in Comparison to an Unmedicated Control Group
2024 · Pharmacopsychiatry · 0 citations
https://doi.org/10.1055/a-2292-1438
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat